RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
about
The value of genomics in dissecting the RAS-network and in guiding therapeutics for RAS-driven cancersHepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancerImpact of somatic mutations on patterns of metastasis in colorectal cancerSurgery for colorectal liver metastases: The evolution of determining prognosisRecent Advances in Chemotherapy and Surgery for Colorectal Liver MetastasesMultisciplinary management of patients with liver metastasis from colorectal cancerSurgical Management of Colorectal Liver Metastases: Prognostic Indicators and the Impact of RAS Mutation StatusKRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis.Multidisciplinary approach of colorectal cancer liver metastases.KRAS mutation in patients undergoing hepatic resection for colorectal liver metastasis: a biomarker of cancer biology or a byproduct of patient selection?RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases.High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort.Association between KRAS mutation and lung metastasis in advanced colorectal cancer.Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancerPrimary Tumor Versus Liver-First Strategy in Patients with Stage IVA Colorectal Cancer: A Propensity Score Analysis of Long-term Outcomes and Recurrence Pattern.KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastasesBRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection.Lymphatic Invasion is an Independent Adverse Prognostic Factor in Patients with Colorectal Liver Metastasis.Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastasesKRAS mutation in lung metastases from colorectal cancer: prognostic implications.Predictors of Safety and Efficacy of 2-Stage Hepatectomy for Bilateral Colorectal Liver Metastases.Evidence of intermetastatic heterogeneity for pathological response and genetic mutations within colorectal liver metastases following preoperative chemotherapy.Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients.Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2.Remnant Liver Ischemia as a Prognostic Factor for Cancer-Specific Survival After Resection of Colorectal Liver Metastases.Management of resectable colorectal lung metastases.Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location.Molecular markers of prognosis and therapeutic targets in metastatic colorectal cancer.Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer.The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis.Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases.Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases.Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study.Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations.Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status.Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
P2860
Q26747403-30108319-F883-4F37-A729-1190CAA088BFQ26772267-5046484A-95E3-4B8F-A8D8-48B96762005BQ26772279-06394EE7-6099-441C-B97E-A0987CE3E0EEQ27694490-781082E4-57A5-46B6-ABE8-FB23433E0781Q28067408-66DD14AA-A704-49CB-81D8-9FB2F6860E58Q28069575-E035199F-7160-4C0A-AE0C-1E21935BCABAQ28075777-EC6D6E7B-A9C5-45B9-95EB-17436AF05B6CQ33591865-A673D61A-EDFB-465A-9F96-B446EB66E13AQ33779859-B37D254D-58B8-4911-B2B9-4501A4CC6E00Q34891212-DDBF6D06-930C-460A-9897-C79FC65C2746Q35054390-7CBED77E-6094-4CE8-9918-F7DFF8836B62Q35677169-E2069EC7-2630-4B16-87C1-498E9DF4C500Q35677827-9E175992-FAD4-4753-91EA-79F12800E04EQ35709696-99FB65D6-9B9B-4F63-9BF3-A415ED9DC520Q35911017-358F70E2-B3A6-4C4B-B0CB-D289CF908C1CQ36016109-1829B01B-0608-4F8E-B932-6885C8BDF985Q36071767-F3B3E06B-CE0D-45D2-AB78-08691A9D998FQ36086837-6289B55C-1B84-42B9-B1AA-71629B86C3C2Q36391787-6E785216-A54E-446F-9232-24080E2DF286Q36416491-B39841C2-D039-4449-B732-2D6F729BD26DQ36465989-5634417B-523F-4DC1-AF1A-C924A9652D39Q36528345-0BF185EF-FC16-4BDB-9CE9-B0BF54AFA1B2Q37047788-3DED473F-0A22-4CB8-B4BA-6FC91065D7C6Q37225348-EE2B4CB6-5643-400F-833F-E3A7C4FA77E8Q38312076-6F2090CE-79BB-4243-9DCC-B206C7CC66E7Q38582586-5C343221-6B24-4A8E-B38E-7573E81F6DF3Q38602133-5D890EA8-1BA9-4403-A20F-E694D8A7B807Q38667176-784692A0-1E03-4013-9ED7-98957433CD56Q38847613-E03D4581-919C-419C-9D42-096007ED089BQ38938329-D4BD17D0-DAA3-489C-9AE4-29DABD5F3AB4Q39038413-CF38238D-0974-492D-B68D-ED35EEFA8BD4Q39238657-958B4283-89B5-4197-BAC2-E14AEC654F82Q39626850-D802A501-BE9F-4E9C-A712-1D4946285653Q39708324-CB9FE485-C3A0-4A2C-8A24-E453EA8F5411Q39722702-6A050B8E-99DB-46D3-AB35-0240151B4F79Q40087648-E0A6B816-284A-4EDC-A628-92D6A63AD4CBQ40108385-3D9982FE-90FB-429C-A618-4B986375A26BQ40226443-56C4804E-FEEB-4B9E-B91B-0734DE96C006Q40317208-A3ECD7E9-8F63-480E-AFF7-680D16D9BD0DQ40515575-CF6201CF-9F40-43C5-B629-15FD8878EB3A
P2860
RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
RAS mutation status predicts s ...... r colorectal liver metastases.
@en
RAS mutation status predicts s ...... r colorectal liver metastases.
@nl
type
label
RAS mutation status predicts s ...... r colorectal liver metastases.
@en
RAS mutation status predicts s ...... r colorectal liver metastases.
@nl
prefLabel
RAS mutation status predicts s ...... r colorectal liver metastases.
@en
RAS mutation status predicts s ...... r colorectal liver metastases.
@nl
P2093
P2860
P1433
P1476
RAS mutation status predicts s ...... r colorectal liver metastases.
@en
P2093
Andreas Andreou
Dipen M Maru
Jean-Nicolas Vauthey
Junichi Shindoh
Steven A Curley
Thomas A Aloia
P2860
P304
619-26; discussion 626-7
P356
10.1097/SLA.0B013E3182A5025A
P407
P577
2013-10-01T00:00:00Z